¿Â¶óÀÎ ½ÉÆ÷Áö¿ò ÇÁ·Î±×·¥

¿ÀÀü ÅëÇÕ°­ÀÇ_»çȸ : ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ¾ÈÁöÇö ÀÌ»ç

Time Title Speaker
08:50-09:00 Welcome Ceremony
´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ȸÀå ÀÎ»ç ±èÇѼö ȸÀå
´ëÇѳ»°úÀÇ»çȸ ȸÀå Ãà»ç ¹Ú±ÙÅ ȸÀå
09:00-10:10 Session I. Current Update 2021 ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ±ÇÁØ °í¹®
ÀüºÏ³»°úÀÇ»çȸ ½ÅºÀÁÖ È¸Àå
09:00-09:20 Hypertension step up - BP variability (HBPM, ABPM, cuffless BP monitoring), 2020 ISH °¡À̵å¶óÀÎreview À̹«¿ë (µ¿±¹ÀÇ´ë)
09:20-09:40 °í¿ë·® ½ºÅ¸Æ¾°ú ¹ÝÀÀÇÏÁö ¾Ê´Â ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚ Ä¡·á-PCSK-9 ¾ïÁ¦Á¦¿Í Evinacumab (ANGPTL3 monoclonal antibody) È«¼øÁØ (°í·ÁÀÇ´ë)
09:40-10:00 ½É¹æ¼¼µ¿ ȯÀÚ, °ú¿¬ 2021³â¿¡µµ Rate control¸¸ Çϸé ÃæºÐÇÒ±î? À̱âÈ« (Àü³²ÀÇ´ë)
10:10-12:00 Session II. Live interactive session with Experts! ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ Á¤³²½Ä °í¹®
Live Talk & Talk, ÀÌ·±Áú¹® Çصµ µÇ³ª¿ä? Panel: ÀÌ»ó (½º¸¶Æ®³»°ú)
½ÅÀÌö (´ë±¸21¼¼±â³»°ú)
10:10-10:20 °¡½¿ÀÌ ¾ÆÇ ȯÀÚ, ¾ðÁ¦, ´©±¸¸¦ Àü¿ø½Ãų±î? ÀÌöȯ (¿ï»êÀÇ´ë)
10:20-10:50 ¾ÈÁ¤Çü Çé½ÉÁõ(chronic coronary syndrome)ȯÀÚ, ÀûÀýÇÏ°Ô Ä¡·áÇϱâ ÀÌöȯ (¿ï»êÀÇ´ë)
10:50-11:15 Coronary CT, coronary calcium score ¿Ã¹Ù¸¥ Çؼ®¹ý Á¶Àͼº (¿¬¼¼ÀÇ´ë)
11:15-11:40 ¼ö¼ú Àü consult, ÀÌ·¸°Ô ´ë´äÇÏÀÚ! ¹èÀåȯ (ÃæºÏÀÇ´ë)
11:40-12:00 ¼ö¼ú Àü, ÈÄ Ç×ÀÀ°íÁ¦ ÀÌ·¸°Ô Á¶ÀýÇÏÀÚ! ¹èÀåȯ (ÃæºÏÀÇ´ë)

¿ÀÈÄ °­ÀÇ A ·ë_ »çȸ : ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ Á¤ÇõÁØ ÀÌ»ç

Time Title Speaker
12:00-13:00 Luncheon symposium ¡¡
12:00-12:20 Cardiorenal disease continuum; CV risk factor to the death Á¶»óÈ£ (ÇѸ²ÀÇ´ë)
12:20-12:40 The management of hypertension with Fimasartan in Korea ½Åµ¿±Ý (ÇѸ²ÀÇ´ë)
13:00-13:40 State of the Art : Çѱ¹ ½ÉÃÊÀ½ÆÄÀÇ ¾îÁ¦¿Í ¿À´Ã, ±×¸®°í ¹Ì·¡ Á¤³²½Ä (Çʸ޵𽺳»°ú)
13:40-15:20 Session III. Systemic disease & Heart ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ±èÁø±¸ °¨»ç
ÀÎõ½Ã³»°úÀÇ»çȸ °ûÇöö ȸÀå
Live Talk & Talk ´ç´¢º´°ú Ç÷°ü Panel:ÃÖ¿µÁÖ (´ç´ç³»°ú)
¿À¹Î¼® (Áß¾Óº¸Èƺ´¿ø)
13:40-14:10 ´ç´¢º´ ȯÀÚ, ½ÉÇ÷°ü ÁúȯÀ» ¿¹¹æÇÏ·Á¸é ¾î¶»°Ô ÇØ¾ß ÇÒ±î? ±ÇÇõ»ó (°¡Å縯ÀÇ´ë)
14:10-14:40 GLP-1 agonist or SGLT2 antagonist, which should be considered 1st for the heart? ¹ÚÁ¤Çö (ÀÎÁ¦ÀÇ´ë)
14:40-15:00 ´ç´¢º´ ȯÀÚ°¡ Àß °É¸®´Â ½ÉÇ÷°üÁúȯ ÃÑÁ¤¸® ½Å¼ºÈñ (ÀÎÇÏÀÇ´ë)
15:00-15:20 ´ç´¢º´¼º ¸»ÃÊ ½Å°æº´Áõ, ¾ðÁ¦ ÀǽÉÇÏ°í ¾î¶»°Ô Ä¡·áÇϳª? ±èÁ¾È­ (¼¼Á¾º´¿ø)

¿ÀÈÄ °­ÀÇ B ·ë_ »çȸ : ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ À̼öÇö ÀÌ»ç

Time Title Speaker
12:00-13:00 Luncheon symposium ¡¡
12:00-12:20 Hypertension treatment options considering BP Variability ±Ç¼º¿í (ÀÎÁ¦ÀÇ´ë)
12:20-12:40 Beta-blockers in the management of hypertension with real world practice ÀÌÀ¯È« (ûÁÖÇѱ¹º´¿ø)
13:00-13:40 State of the Art : Çѱ¹ ½ÉÃÊÀ½ÆÄÀÇ ¾îÁ¦¿Í ¿À´Ã, ±×¸®°í ¹Ì·¡ Á¤³²½Ä (Çʸ޵𽺳»°ú)
13:40-15:10 Session IV. Àü½ÅÁúȯ°ú ½ÉÀå ÁÂÀå: ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ ³ëÅÂÈ£ °¨»ç
°æ±âµµ³»°úÀÇ»çȸ Àå¿õ±â ȸÀå
13:40-14:10 Åëdz, ¿ä»ê°ú ½ÉÀå ¼ÛÁ¤¼ö (Áß¾ÓÀÇ´ë)
14:10-14:40 ½ÉÀåÁúȯ Áø´Ü¿¡ À¯¿ëÇÑ serologic marker ±èÇü¼· (°è¸íÀÇ´ë)
14:40-15:00 ¼ö¸éÀå¾Ö¿Í ½ÉÇ÷°üÁúȯ °­±â¿î (À»ÁöÀÇ´ë)
15:00-15:20 °¡½¿ÀÌ ´ä´äÇÑ È¯ÀÚ, ¾ðÁ¦ ¾î¶»°Ô Á¤½Å°Ç°­ÀÇÇаú·Î Àü¿ø ½Ãų±î? ½Å¿µÃ¶ (¼º±Õ°üÀÇ´ë)